Since the sequence homology between exenatide and human GLP-1 is only 53%, 40% to 60% of patients develop antiexenatide antibodies, though in most cases antibody development does not reduce the efficacy of exenatide treatment [44,49-51]
Symptoms to watch for include palpitations, dizziness, or fainting
Larazotide functions by tightening these loose junctions, effectively closing the gaps in the gut lining
SOLIQUA 100/33 (insulin glargine and lixisenatide injection), for subcutaneous use [prescribing information]
A separate study following participants from the STEP 1 clinical trial found that weight, waist circumference and cardiometabolic risk factors largely returned toward baseline levels within 12 months of stopping the medication
In terms of side effects and tolerability, the advantage goes to neither (comparable)